Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.88 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088128 | 0.95 | MAPT (0.97) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL230079 | 0.94 | MAPT (1.00) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL855166 | 0.90 | MAPT (0.77) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL14050118 | 0.90 | MAPT (0.76) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL14736626 | 0.88 | MAPT (0.74) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL13263650 | 0.85 | MAPT (0.69) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL4485011 | 0.83 | MAPT (0.68) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL17933567 | 0.83 | MAPT (0.72) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL2929122 | 0.82 | MAPT (0.66) | MAPTNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL17933568 | 0.82 | MAPT (0.70) | MAPTNPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1983992-A2 | 2-IMINO-BENZIMIDAZOLES | Abbott Laboratories (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | MAPT 2918/4885NPC1 234/4885RAB9A 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.